Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy

 
• By Alaric DeArment

The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.

Digital illustration of Cancer cell in colour background
• Source: Shutterstock

More from Strategy

More from Business